🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

AMN Healthcare names Tomya Watt as new Chief People Officer

Published 31/10/2024, 14:44
AMN
-

DALLAS - AMN Healthcare (NYSE:AMN), a provider of talent solutions for healthcare organizations, announced the upcoming addition of Tomya Watt to its executive team as Chief People Officer, effective January 13, 2025. Watt brings over twenty years of strategic human resources experience in the healthcare and staffing industries to the role.

Watt's appointment follows the recent retirement of Carolyn Kenny, marking a new chapter in AMN Healthcare's strategic vision. President and CEO Cary Grace expressed confidence in Watt's ability to enhance the company's human resources function, citing her visionary leadership and comprehensive expertise.

In her most recent position at Memorial Sloan Kettering Cancer Center, Watt served as interim Chief Human Resources Officer and Chief Diversity Officer. There, she managed a 170-person team and oversaw all HR functions for the organization, which employs 22,000 people and operates with a budget of $6.7 billion. Her efforts at Memorial Sloan Kettering included implementing innovative strategies to boost organizational effectiveness and employee engagement, leveraging real-time data for better decision-making, optimizing talent acquisition to reduce costs, and advancing inclusion and diversity to improve patient experiences.

Prior to her tenure at Memorial Sloan Kettering, Watt held senior roles at Kelly Services (NASDAQ:KELYA), Inc. and Comerica (NYSE:CMA) Bank. Her academic credentials include an MBA from Howard University and a BA in Economics from Spelman College.

Watt is also actively involved in the industry as a member of the Gartner (NYSE:IT) CHRO Healthcare Group and serves on the advisory board of The Conference Board's Labor Market Center.

AMN Healthcare is recognized for its leadership in providing comprehensive networks of quality healthcare professionals and integrated workforce technologies to healthcare organizations across the United States.

This announcement is based on a press release statement. For further details on AMN Healthcare's leadership team, visit the company's website.

In other recent news, AMN Healthcare experienced significant changes in its leadership and financial performance. The company appointed Brian Scott as Chief Financial Officer and Chief Operating Officer, following the departure of Jeffrey Knudson. Scott's appointment is considered strategic, given his previous successful tenure with AMN Healthcare. In addition, the company expanded its board with the addition of healthcare veteran James H. Hinton, whose extensive experience is expected to contribute significantly to the company's strategic direction.

AMN Healthcare reported Q1 revenues that met market expectations at $821 million, despite a 37% year-over-year drop in revenues from the Nurse and Allied Solutions segment. However, the Physician and Leadership Solutions segment and Language Services showed promising growth, with increases of 14% and 16% respectively. The company also reported strong financial results that exceeded analyst expectations, primarily due to effective margin management.

BMO Capital Markets maintained its Outperform rating on the company, revising its price target upwards to $71. This confidence in the company's financial stability was echoed in the positive outlook expressed by AMN's CEO, Cary Grace. On the other hand, BofA Securities adjusted its stance on AMN Healthcare, moving the rating from Neutral to Underperform, reflecting a lowered expectation for the company's future earnings. These are the recent developments for AMN Healthcare.

InvestingPro Insights

As AMN Healthcare prepares to welcome Tomya Watt as its new Chief People Officer, the company faces both challenges and opportunities in the current market landscape. According to InvestingPro data, AMN's market capitalization stands at $1.48 billion, reflecting its significant presence in the healthcare staffing industry.

Despite the company's strong position, recent financial metrics suggest a period of adjustment. AMN's revenue for the last twelve months as of Q2 2024 was $3.23 billion, marking a 26.21% decline. This aligns with an InvestingPro Tip indicating that analysts anticipate a sales decline in the current year. The company's profitability, however, remains intact with a P/E ratio of 15.0, suggesting that investors are still valuing the company's earnings potential.

Another InvestingPro Tip notes that AMN's stock is trading near its 52-week low, with the price having fallen significantly over the last three months. This could present an opportunity for investors who believe in the company's long-term prospects, especially considering the strategic importance of Watt's appointment in strengthening AMN's human resources capabilities.

It's worth noting that AMN Healthcare does not pay a dividend to shareholders, focusing instead on reinvesting in the business. This strategy may be particularly important as the company navigates the current market conditions and prepares for future growth under new leadership.

InvestingPro offers additional insights, with 7 more tips available for AMN Healthcare, providing a deeper analysis for investors interested in the company's future trajectory amidst these leadership changes and market challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.